Integrilin
eptifibatide
Table of contents
Overview
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.
If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Integrilin
|
Agency product number |
EMEA/H/C/000230
|
Active substance |
eptifibatide
|
International non-proprietary name (INN) or common name |
eptifibatide
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
B01AC16
|
Publication details | |
---|---|
Marketing-authorisation holder |
GlaxoSmithKline (Ireland) Limited
|
Revision |
26
|
Date of issue of marketing authorisation valid throughout the European Union |
01/07/1999
|
Contact address |
12 Riverwalk |
Product information
24/09/2021 Integrilin - EMEA/H/C/000230 - N/0088
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antithrombotic agents
Therapeutic indication
Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin.
Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes.
Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (PTCA).